Literature DB >> 23154301

Sensory gating, cannabinoids and schizophrenia.

Dilshani W N Dissanayake1, Robert Mason, Charles A Marsden.   

Abstract

Sensory gating, a mandatory process in early information processing, has been found to be defective in neuropsychiatric diseases such as schizophrenia. Understanding the neurobiology of sensory gating may provide insight into unravelling the neurobiology of information processing and to yet unanswered queries on the pathophysiology of disabling neuropsychiatric diseases. The endocannabinoid system has been linked to the pathophysiology of schizophrenia. Furthermore, cannabinoids disrupt sensory gating in animals and humans which supports the hypothesis that the disruption of sensory gating by alterations in the endocannabinoid system is a significant factor in the etiology of schizophrenia. Based on the above hypothesis this article reviews the sensory gating process in relation to the auditory conditioning-test paradigm with an emphasis on its association with the endocannabinoid system and schizophrenia.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154301     DOI: 10.1016/j.neuropharm.2012.10.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

Review 1.  Differential Susceptibility of the Developing Brain to Contextual Adversity and Stress.

Authors:  W Thomas Boyce
Journal:  Neuropsychopharmacology       Date:  2015-09-22       Impact factor: 7.853

Review 2.  Brain Excitability in Tension-Type Headache: a Separate Entity from Migraine?

Authors:  Wei-Ta Chen; Fu-Jung Hsiao; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2021-01-07

3.  Effects of Ketamine on Basal Gamma Band Oscillation and Sensory Gating in Prefrontal Cortex of Awake Rats.

Authors:  Renli Qi; Jinghui Li; Xujun Wu; Xin Geng; Nanhui Chen; Hualin Yu
Journal:  Neurosci Bull       Date:  2018-01-29       Impact factor: 5.203

4.  State-dependent changes in auditory sensory gating in different cortical areas in rats.

Authors:  Renli Qi; Minghong Li; Yuanye Ma; Nanhui Chen
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

5.  Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.

Authors:  Raquel Levin; Fernanda F Peres; Valéria Almeida; Mariana B Calzavara; Antonio W Zuardi; Jaime E C Hallak; José Alexandre S Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

6.  Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users.

Authors:  Samantha J Broyd; Lisa-marie Greenwood; Hendrika H van Hell; Rodney J Croft; Hannah Coyle; Ben Lee-Bates; Juanita Todd; Stuart J Johnstone; Patricia T Michie; Nadia Solowij
Journal:  Neural Plast       Date:  2016-02-25       Impact factor: 3.599

7.  Vestibular Migraine Patients Show Lack of Habituation in Auditory Middle Latency Responses to Repetitive Stimuli: Comparison With Meniere's Disease Patients.

Authors:  Toshihisa Murofushi; Fumiyuki Goto; Masahito Tsubota
Journal:  Front Neurol       Date:  2020-02-20       Impact factor: 4.003

8.  Somatosensory Gating Responses Are Associated with Prognosis in Patients with Migraine.

Authors:  Fu-Jung Hsiao; Wei-Ta Chen; Yen-Feng Wang; Shih-Pin Chen; Kuan-Lin Lai; Hung-Yu Liu; Li-Ling Hope Pan; Shuu-Jiun Wang
Journal:  Brain Sci       Date:  2021-01-28

9.  CB2 cannabinoid receptor expression is increased in 129S1/SvImJ mice: behavioral consequences.

Authors:  Marc Ten-Blanco; Inmaculada Pereda-Pérez; Cristina Izquierdo-Luengo; Fernando Berrendero
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

10.  Prefrontal inhibition of neuronal Kv 7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality.

Authors:  Jing Wang; Wenwen Yu; Qin Gao; Chuanxia Ju; KeWei Wang
Journal:  Br J Pharmacol       Date:  2020-09-17       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.